cyclin-dependent kinase-9 inhibitor (Pharos IBT)

N/A

Report date: 2025/03/19 11:37:51
NME

Base Information

Drug Namecyclin-dependent kinase-9 inhibitor (Pharos IBT)
Drug Alias NameCDK9 inhibitor (Pharos IBT)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitors
TargetsCyclin-dependent kinase 9
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPharos iBio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPharos iBio Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A